Kolexia
Saada-Bouzid Esma Oncologie médicale
Saada-Bouzid Esma
Oncologie médicale
Centre Antoine Lacassagne
Nice, France
257 Activités
427 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome épidermoïde Carcinomes Sarcomes Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou Récidive tumorale locale Métastase tumorale Tumeurs des tissus mous Tumeurs du poumon

Collaborateurs

Voir plus
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Penel Nicolas
Penel Nicolas
Centre Oscar-Lambret, Lille, France
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Bompas Emmanuelle
Bompas Emmanuelle
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
MSD
17 collaboration(s)
Dernière en 2023
Merck-Serono
14 collaboration(s)
Dernière en 2023
BMS
12 collaboration(s)
Dernière en 2021
Seagen
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
IMMUNONET: A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies
Essai Clinique (NETRIS Pharma)   06 mars 2024
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
The Lancet. Healthy longevity   05 mars 2024
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors: Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Essai Clinique (Merus N.V.)   01 mars 2024
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation: A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a Kras Mutation
Essai Clinique (Cardiff Oncology)   29 février 2024
CHIC-STS01: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   26 février 2024
AcSé: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Essai Clinique (Unicancer)   26 février 2024
ELAN-UNFIT: Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Essai Clinique (Merck-Serono)   07 février 2024
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors: A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
Essai Clinique (Calico Life Sciences LLC)   30 janvier 2024
Improved nationwide survival of sarcoma patients with a network of reference centers.
Annals of oncology : official journal of the European Society for Medical Oncology   19 janvier 2024